-- Days : -- HRS : -- MIN : -- SEC

Register Now →

News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|November 17, 2023

Myelodysplastic Syndrome (MDS) Overview

Ryan Haumschild, PharmD, MS, MBA, CPEL, opens the discussion by defining the MDS disease state.

Episodes in this series

EP. 1 Myelodysplastic Syndrome (MDS) Overview

EP. 1 Myelodysplastic Syndrome (MDS) Overview

EP. 2 Distinguishing Between Different MDS Subtypes

EP. 2 Distinguishing Between Different MDS Subtypes

EP. 3 MDS-Related Complications Impacting Patient Quality of Life

EP. 3 MDS-Related Complications Impacting Patient Quality of Life

EP. 4 Economic Implications of MDS Management

EP. 4 Economic Implications of MDS Management

EP. 5 Examining Treatment Algorithms for MDS

EP. 5 Examining Treatment Algorithms for MDS

EP. 6 Growth Factor and Stem Cell Transplant Candidacy in MDS

EP. 6 Growth Factor and Stem Cell Transplant Candidacy in MDS

EP. 7 Novel Agents Contributing to Evolving MDS Therapy Strategies

EP. 7 Novel Agents Contributing to Evolving MDS Therapy Strategies

EP. 8 Benefits of Oral Therapies In MDS Treatment Adherence

EP. 8 Benefits of Oral Therapies In MDS Treatment Adherence

EP. 9 Adapting MDS Treatment Approach

EP. 9 Adapting MDS Treatment Approach

EP. 10 Novel Therapy Impact on Patient Quality of Life

EP. 10 Novel Therapy Impact on Patient Quality of Life

Video 11 - "Multidisciplinary Care Driving Effective MDS Treatment"

EP. 11 Multidisciplinary Care Driving Effective MDS Treatment

Video 12 - "Payor Considerations In MDS Management"

EP. 12 Payor Considerations In MDS Management

Video 12 - "Payor Considerations In MDS Management"

EP. 13 Navigating Insurance-Related Challenges Associated With MDS Treatment

Video 12 - "Payor Considerations In MDS Management"

EP. 14 Key Considerations Surrounding MDS Treatment

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Vitamin D3 | Image Credit: Adisak - stock.adobe.com

High-Dose Vitamin D3 Fails to Improve PFS in Phase 3 Metastatic CRC Trial

ByBrooke McCormick

August 6th 2026

Katherine Wilemon, CEO of the Family Heart Foundation

Almost No Public Awareness of Lp(a), Elevated CVD Risk in the US: Katherine Wilemon

ByPearl Steinzor,Katherine Wilemon

August 6th 2026

Eosinophilic esophagitis | Image Credit: syahrir - stock.adobe.com

Patients With MASLD Had More Than 2 Times Higher Odds of Eosinophilic Esophagitis Across Age Groups

ByBrooke McCormick

August 6th 2026

Experts featured in this series.

Translating PFS Data for Patients: How Community Oncologists Communicate Trial Outcomes in RRFL

ByRyan Haumschild, PharmD, MS, MBA, CPEL,Christina Poh, MD,Tara Graff DO, MS

August 6th 2026

Avoiding TNF Cycling: When to Switch Drug Classes in Rheumatoid Arthritis

ByJulia Buchfuhrer, DO

August 6th 2026

Trending on AJMC

FDA Approves Moderna’s mRNA Flu Vaccine After Phase 3 Success

OneOncology Partners With OpenEvidence to Give Physicians Access Within Clinical Workflows

High-Dose Vitamin D3 Fails to Improve PFS in Phase 3 Metastatic CRC Trial

Patients With MASLD Had More Than 2 Times Higher Odds of Eosinophilic Esophagitis Across Age Groups

AHA Proposes Staging System for Pediatric Cardiogenic Shock